Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

ed net loss per common share for the six

months ended June 30, 2008 and 2007, respectively. Research and

development expense and general and administrative expense includes

$623 and $706 of non-cash operating expenses determined in accordance

with SFAS No. 123R for the six months ended June 30, 2008.

Anadys Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 30, December 31,

2008 2007

(Unaudited) (Audited)

Assets

Cash, cash equivalents and securities

available-for-sale $ 42,112 $ 56,495

Other current assets 1,276 1,004

Noncurrent assets 3,560 4,027

Total assets $ 46,948 $ 61,526

Liabilities and Stockholders' Equity

Current liabilities $ 4,140 $ 5,415

Other long-term liabilities 124 432

Stockholders' equity 42,684 55,679

Total liabilities and

stockholders' equity $ 46,948 $ 61,526


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
(Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2
... 28, 2011 Cell Therapeutics, Inc. (CTI) (Nasdaq and ... the WBBA Life Science Innovation Northwest Conference on Thursday, ... 607 of the Washington State Conference Center, Seattle, Washington. ... 3, 201110:25 AM PST/1:25 PM EST/7:25 PM CETRoom 607, ...
... a professor of chemistry at Penn State University, has developed ... zinc selenide -- a light-yellow compound that can be used ... allows for a more effective and liberal manipulation of light, ... Such technology could be applied to the development of improved ...
... 25, 2011 GeoVax Labs, Inc. (OTC Bulletin Board: ... and tests innovative HIV/AIDS vaccines, today announced its financial results ... GeoVax reported a net loss of $478,784 for ... a net loss of $843,275 for the comparable period in ...
Cached Biology Technology:New kind of optical fiber developed 2New kind of optical fiber developed 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 2GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 3GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 4GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 5GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results 6
(Date:10/19/2014)... electricity access in India over the last 30 ... carbon emissions growth during that time, according to ... Nature Climate Change ., "Energy access is fundamental ... of life, including education, communication, and health," says ... , While increased energy access is widely agreed ...
(Date:10/17/2014)... This news release is available in German . ... need millions of sperms every day in order to reproduce? ... questions are the topic of the latest issue of the ... 16th, 2014). The evolutionary biologist Steven Ramm from Bielefeld University ... nature, it is not unusual for a female to copulate ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Sperm wars 2New report synthesizes best available science on management of moist mixed-conifer forests 2
... have discovered a way to target the immune system to ... Researchers also found evidence that the same mechanism may operate ... online edition of Nature . The findings provide ... harness the immune system to fight cancer and other diseases. ...
... In a loud, crowded restaurant, having the ability to focus ... critical. Nerve cells in the brain face similar challenges in ... this process appears to be oxytocin, typically known as the ... bonding. , , In a study appearing online August 4 ...
... other international plans to evaluate obesity prevention efforts, and ... having their intended impact, says a new report from ... the report concluded that more systematic and routine evaluations ... policies are being implemented and which interventions work best. ...
Cached Biology News:Mechanism offers promising new approach for harnessing the immune system to fight cancer 2Mechanism offers promising new approach for harnessing the immune system to fight cancer 3Study reveals potential role of 'love hormone' oxytocin in brain function 2New IOM report lays out plan to determine effectiveness of obesity prevention efforts 2
... MiniPrep series of robotic workstations is designed ... MiniPrep is the ideal automation platform for ... routine laboratory procedures, improving throughput, process consistency ... for MiniPrep software allows you to control ...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
... HDAC4 - ChIP Grade HDAC4 is ... histone deacetylases, which consists of 1084 amino ... similar to the deacetylase domain of yeast ... the nucleus and cytoplasm in a process ...
Biology Products: